MNMarlies Noordzij

Marlies Noordzij

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Marlies Noordzij has a total of 99 co-authors. Here are the top co-authors by number of shared publications:

  • Friedo Wilhelm Dekker

    Department of Clinical Epidemiology, Leiden University Medical Center , Leiden

    14 shared publications
  • Kitty J. Jager

    European Renal Association-European Dialysis and Transplant Association (ERA-EDTA) Registry, Department of Medical Informatics, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands

    10 shared publications
  • Carmine Zoccali

    Institute of Molecular Biology and Genetics (Biogem), Ariano Irpino, Italy

    7 shared publications
  • Elisabeth W. Boeschoten

    Hans Mak Institute, Naarden

    5 shared publications
  • Johanna C. Korevaar

    Department of Clinical Epidemiology, Biostatistics and Bioinformatics, Academic Medical Center, University of Amsterdam, Amsterdam

    5 shared publications
  • Raymond T. Krediet

    Department of Nephrology, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands

    5 shared publications

Latest Publications

  • SP682CHANGES IN CLINICAL PARAMETERS RELATED TO THE TRANSITION FROM DIALYSIS TO KIDNEY TRANSPLANTATION: RESULTS FROM THE ERA−EDTA REGISTRY

    by Pichaya Tantiyavarong, Anneke Kramer, James Heaf, Patrik Finne, Ziad Massy, Kitty Jager, Marlies Noordzij

    INTRODUCTION AND AIMS: During dialysis treatment disturbances in clinical parameters such as anemia, disturbed mineral metabolism and dyslipidemia commonly occur. Kidney transplantation (TX) should improve many of these disturbances, but its exact impact is incompletely understood. We therefore aimed to assess changes in clinical parameters in the period after the transition from chronic dialysis to TX.

  • Patient survival on dialysis in Korea: a different story?

    by Marlies Noordzij, Kitty J. Jager


  • Open Access

    Use of vascular access for haemodialysis in Europe: a report from the ERA-EDTA Registry

    by Marlies Noordzij, Kitty J. Jager, Sabine N. van der Veer, Reinhard Kramar, Frederic Collart, James G. Heaf, Olivera Stojceva-Taneva, Torbjørn Leivestad, Jadranka Buturovic-Ponikvar, Manuel Benítez Sánchez, et al.

    Although arteriovenous fistulas (AVFs) are actively promoted, their use at the start of haemodialysis (HD) seems to be decreasing worldwide. In this paper, we describe recent trends in incidence and prevalence of vascular access types in Europe from 2005 to 2009 and their relationship with patient characteristics and survival. Ten European renal registries participating in the ERA-EDTA Registry provided data on incidence (n = 13 044) and/or prevalence (n = 75 715) of vascular access types. We used logistic regression to assess which factors influence the likelihood to be treated with an AVF rather than another type. The use of AVFs at the start of HD showed a significant decreasing trend from 42% in 2005 to 32% in 2009 (P < 0.0001), while the use of central venous catheters (CVCs) increased from 58 to 68% (P < 0.0001). A similar evolution pattern was observed for the prevalence; use of AVFs decreased from 66 to 62% and use of CVCs increased from 28 to 32%. There was a large international variation in the use of the different vascular access types. Female patients [adjusted odds ratio: 0.84, 95% confidence interval (CI): 0.78–0.90] and those ≥80 years (0.77, 95% CI: 0.67–0.90) were least likely to start HD with an AVF. In Europe, there is a decreasing trend in the use of AVFs and an increasing trend in the use of CVCs at the start and after the start of HD. We cannot explain all between-country variations we found, and more research is needed to clarify how healthcare around vascular access is organized in Europe.


  • Open Access

    Renal replacement therapy in Ukraine: epidemiology and international comparisons

    by Inna Kolesnyk, Marlies Noordzij, Mykola Kolesnyk, Mykola Kulyzky, Kitty J. Jager

    Little is known about the status of renal replacement therapy (RRT) in the post-Soviet countries. We therefore investigated the epidemiology and treatment outcomes of RRT in Ukrainian patients and put the results into an international perspective. Data from the Ukrainian National Renal Registry for patients on RRT between 1 January 2010 and 31 December 2012 were selected. We calculated the incidence and prevalence of RRT per million population (pmp) and the 3-, 12- and 24-month patient survival using the Kaplan–Meier method and Cox regression. There were 5985 prevalent patients on RRT on 31 December 2012 (131.2 pmp). Mean age was 46.5 ± 13.8 years, 56% men and 74% received haemodialysis (HD), while peritoneal dialysis and kidney transplantation both represented 13%. The most common cause of end-stage renal disease was glomerulonephritis (51%), while only 12% had diabetes. In 2012, 1129 patients started dialysis (incidence 24.8 pmp), with 80% on HD. Mean age was 48 ± 14 years, 58% men and 20% had diabetes. Three, 12- and 24-month patient survival on dialysis was 95.1%, 86.0% and 76.4%, respectively. The transplant rate in 2012 was 2.1 pmp. The incidence and prevalence of RRT and the transplantation rate in Ukraine are among the lowest in Europe, suggesting that the need for RRT is not being met. Strategies to reduce the RRT deficit include the development and improvement of transplantation and home-based dialysis programmes. Further evaluation of the quality of Ukrainian RRT care is needed.


  • Open Access

    Renal replacement therapy in Europe: a summary of the 2011 ERA-EDTA Registry Annual Report

    by Marlies Noordzij, Anneke Kramer, José M. Abad Diez, Ramón Alonso de la Torre, Emma Arcos Fuster, Boris T. Bikbov, Marjolein Bonthuis, Encarnación Bouzas Caamaño, S. Ala, Fergus J. Caskey, et al.

    This article provides a summary of the 2011 ERA–EDTA Registry Annual Report (available at www.era-edta-reg.org). Data on renal replacement therapy (RRT) for end-stage renal disease (ESRD) from national and regional renal registries in 30 countries in Europe and bordering the Mediterranean Sea were used. From 27 registries, individual patient data were received, whereas 17 registries contributed data in aggregated form. We present the incidence and prevalence of RRT, and renal transplant rates in 2011. In addition, survival probabilities and expected remaining lifetimes were calculated for those registries providing individual patient data. The overall unadjusted incidence rate of RRT in 2011 among all registries reporting to the ERA–EDTA Registry was 117 per million population (pmp) (n = 71.631). Incidence rates varied from 24 pmp in Ukraine to 238 pmp in Turkey. The overall unadjusted prevalence of RRT for ESRD on 31 December 2011 was 692 pmp (n = 425 824). The highest prevalence was reported by Portugal (1662 pmp) and the lowest by Ukraine (131 pmp). Among all registries, a total of 22 814 renal transplantations were performed (37 pmp). The highest overall transplant rate was reported from Spain, Cantabria (81 pmp), whereas the highest rate of living donor transplants was reported from Turkey (39 pmp). For patients who started RRT between 2002 and 2006, the unadjusted 5-year patient survival on RRT was 46.8% [95% confidence interval (CI) 46.6–47.0], and on dialysis 39.3% (95% CI 39.2–39.4). The unadjusted 5-year patient survival after the first renal transplantation performed between 2002 and 2006 was 86.7% (95% CI 86.2–87.2) for kidneys from deceased donors and 94.3% (95% CI 93.6–95.0) for kidneys from living donors.


  • Top Cited Papers
    Open Access

    When do we need competing risks methods for survival analysis in nephrology?

    by Marlies Noordzij, Karen Leffondré, Karlijn J. van Stralen, Carmine Zoccali, Friedo W. Dekker, Kitty J. Jager

    Survival analyses are commonly applied to study death or other events of interest. In such analyses, so-called competing risks may form an important problem. A competing risk is an event that either hinders the observation of the event of interest or modifies the chance that this event occurs. For example, when studying death on dialysis, receiving a kidney transplant is an event that competes with the event of interest. Conventional methods for survival analysis ignoring the competing event(s), such as the Kaplan–Meier method and standard Cox proportional hazards regression, may be inappropriate in the presence of competing risks, and alternative methods specifically designed for analysing competing risks data should then be applied. This problem deserves more attention in nephrology research and in the current article, we therefore explain the problem of competing risks in survival analysis and how using different techniques may affect study results.


  • Open Access

    Survival in dialysis patients is not different between patients with diabetes as primary renal disease and patients with diabetes as a co-morbid condition

    by the NECOSAD Study Group, Marielle A Schroijen, Olaf M Dekkers, Diana C Grootendorst, Marlies Noordzij, Johannes A Romijn, Raymond T Krediet, Elisabeth W Boeschoten, Friedo W Dekker

    On dialysis, survival among patients with diabetes mellitus is inferior to survival of non-diabetic patients. We hypothesized that patients with diabetes as primary renal disease have worse survival compared to patients with diabetes as a co-morbid condition and aimed to compare all-cause mortality between these patient groups.


  • Adding Up the Evidence: Systematic Reviews and Meta-Analyses

    by Marlies Noordzij, Carmine Zoccali, Friedo W. Dekker, Kitty J. Jager

    A systematic review aims to synthesize all available individual studies on a certain topic and uses explicit and reproducible methods for searching the literature, while a meta-analysis is a mathematical synthesis of the results of these individual studies. Because of the explosion of information in the scientific literature, these study designs can be useful tools to summarize the knowledge on a particular subject. In addition, combining individual studies in a meta-analysis increases statistical power, resulting in more precise effect estimates. Even though all parts of the specific methodology of systematic reviews include steps to minimize bias, both investigators and readers should be aware of potential biases like poor study quality and heterogeneity between studies. This paper explains how systematic reviews and meta-analyses should be performed and how to critically appraise them, based on an example from the nephrology literature.


  • Sample Size Calculations

    by Marlies Noordzij, Friedo W. Dekker, Carmine Zoccali, Kitty J. Jager

    The sample size is the number of patients or other experimental units that need to be included in a study to answer the research question. Pre-study calculation of the sample size is important; if a sample size is too small, one will not be able to detect an effect, while a sample that is too large may be a waste of time and money. Methods to calculate the sample size are explained in statistical textbooks, but because there are many different formulas available, it can be difficult for investigators to decide which method to use. Moreover, these calculations are prone to errors, because small changes in the selected parameters can lead to large differences in the sample size. This paper explains the basic principles of sample size calculations and demonstrates how to perform such a calculation for a simple study design.


  • Progression of aortic calcification is associated with disorders of mineral metabolism and mortality in chronic dialysis patients

    by M. Noordzij, E. M. Cranenburg, L. F. Engelsman, M. M. Hermans, E. W. Boeschoten, V. M. Brandenburg, W. J. W. Bos, J. P. Kooman, F. W. Dekker, M. Ketteler, et al.

    Previous studies have shown that simple imaging methods may be useful for detection of vascular calcifications in dialysis patients. Based on annual, plain chest X-rays during follow-up on dialysis, we studied the associations of mineral metabolism with the presence and progression of aortic calcification. In addition, we assessed the impact of aortic calcification on mortality. Three hundred and eighty-four patients who started haemodialysis or peritoneal dialysis between 1997 and 2007 were included (age 61 ± 15 years, 64% male, 61% haemodialysis). Annual chest X-rays were screened for calcification in the aortic arch, and patients were categorized as having no, moderate or severe calcification. Progression was defined as an increase in calcification category during follow-up on dialysis. At baseline, 96 (25%) patients had severe, 205 (53%) patients had moderate and 83 (22%) patients had no aortic calcification. For 237 of the 288 patients with no or moderate calcifications at baseline, X-rays were available for follow-up. During follow-up (mean 2.3 years), aortic calcification progressed in 71 patients (30%). We found that baseline plasma calcium > 9.5 mg/dL and iPTH > 300 pg/mL were associated with progression [odds ratios of 3.1, 95% confidence interval (1.2-8.2) and 4.4 (1.4-14.1), respectively]. Progression of aortic calcification was significantly associated with increased risk of all-cause mortality (hazard ratio: 1.9; 95% CI: 1.2-3.1) and cardiovascular mortality (hazard ratio: 2.7; 95% CI: 1.3-5.6). Aortic calcification progressed in almost a third of the patients during dialysis. Hypercalcaemia and hyperparathyroidism were associated with an increased risk of progression. Progression of aortic calcification was significantly related to an increased mortality risk.